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(57) ABSTRACT 
The present invention provides novel isolated nucleic acids 
encoding antigenic proteins derived from Sarcocystis neu 
rona, or unique fragments thereof. In particular, the inven 
tion provides novel isolated nucleic acids encoding mem 
brane-associated polypeptides SnSAG2, SnSAG3, and 
SnSAG4. Also provided are puri?ed antigenic polypeptide 
fragments encoded by the novel nucleic acid sequences set 
forth herein that encode for SnSAG2, SnSAG3, and 
SnSAG4. Also provided are isolated nucleic acids capable of 
selectively hybridizing With the nucleic acid from Sarcocys 
tis neurona. The invention also provides vectors comprising 
the nucleic acids of the invention encoding an antigenic 
protein derived from Sarcocystis neurona or a unique frag 
ment thereof and provides the vector in a host capable of 
expressing the polypeptide encoded by that nucleic acid. 
Finally, the invention provides puri?ed polyclonal and/or 
monoclonal antibodies speci?cally reactive With Sarcocystis 
neurona and a method of detection of Sarcocystis neurona 
utilizing the antibodies of the invention. 
17 Claims, 8 Drawing Sheets 
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NUCLEIC ACIDS ENCODING SARCOC YST IS 
NE URONA ANTIGEN AND USES THEREOF 
The present application is a continuation of US. utility 
patent application Ser. No. 10/369,430, ?led on Feb. 19, 
2003 now US. Pat. No. 7,056,733, Which claims the bene?t 
of priority of US. provisional patent application No. 60/357, 
479, ?led Feb. 15, 2002, the disclosures of Which are 
incorporated herein in their entirety by reference. 
TECHNICAL FIELD 
The present invention relates to nucleic acids of Sarco 
cyslis neurona. In particular, the present invention relates to 
nucleic acids of Sarcocyslis neurona and to nucleic acid 
reagents and antibodies for use in methods of detection and 
prevention of Sarcocyslis neurona infection. More particu 
larly, the present invention relates to novel nucleic acid 
sequences of Sarcocyslis neurona and to utiliZation thereof 
including primers, probes, antigen/antibody diagnostic kits, 
vectors for production of peptides encoding the novel 
nucleic acids, and to antigenic proteins and vaccines against 
Sarcocyslis neurona. 
BACKGROUND OF THE INVENTION 
Sarcocyslis neurona is an apicomplexan parasite that is 
the primary cause of equine protoZoal myeloencephalitis 
(EPM; Dubey et al., 1991), Which is a common and debili 
tating infectious disease that affects the central nervous 
system of horses. S. neurona is related to the human and 
animal pathogen Toxoplasma gondii and to the important 
veterinary pathogen Neospora spp. The geographic range of 
S. neurona appears to be limited to the Western hemisphere, 
thus EPM primarily affects horses in the Americas. 
De?nitive antemortem diagnosis of EPM remains exceed 
ingly dif?cult, for a variety of reasons. Horses a?licted With 
EPM exhibit signs that are similar to a number of different 
neurological disorders (MacKay et al., 2000). Furthermore, 
S. neurona infection does not equate to disease, since only 
a small proportion of seropositive horses Will suffer from 
EPM (MacKay et al., 2000); as a consequence, the detection 
of anti-S. neurona antibodies in serum provides little diag 
nostic information other than indicating previous exposure 
to the parasite. Analysis of cerebrospinal ?uid (CSF) to 
reveal intrathecal antibody production has improved the 
predictive value of antibody detection for EPM diagnosis. 
HoWever, interpretation of CSF antibody presence can be 
confounded by contamination of the CSF sample With 
minute amounts of serum antibodies (Miller et al., 1999). 
Other contemporary diagnostic assays provide only 
mediocre predictive value for EPM diagnosis. Western blot 
analysis (a.k.a., immunoblot) of crude S. neurona lysate 
remains the principal immunodiagnostic test that is used to 
detect antibodies in suspect EPM horses (Granstrom et al., 
1993). The assay relies on the recognition of several anti 
gens, primarily in the loW molecular Weight range, by 
serum/CSF antibodies (Dubey et al., 2001b; Granstrom et 
al., 1993; MacKay et al., 2000). Unfortunately, Western blot 
analysis is primarily a research tool that is relatively labo 
rious and someWhat hindered by subjectivity, so any 
improvements to the immunoblot are of limited value. While 
the immunoblot has been utiliZed for a number of years to 
help diagnose EPM, it is a ?rst-generation test that needs to 
be replaced With improved assays based on simpli?ed, and 
thus more reliable, techniques that are more appropriate for 
diagnostic use. 
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Nucleic acid ampli?cation assays (polymerase chain reac 
tion; PCR) for S. neurona detection have been developed 
based on the S. neurona ribosomal RNA genes (Fenger et al., 
1994; Marsh et al., 1996). These PCR-based assays detect 
the presence of S. neurona DNA, and therefore the parasite, 
in the horse, so they can provide a de?nitive indication of 
active infection. HoWever, prior to the present invention, 
these nucleic acid-based tests have been inherently unreli 
able. Speci?cally, parasites may be very feW or non-existent 
in a CSF sample, so there Will be feW or no available target 
molecules (i.e., parasite genomic DNA) for PCR ampli?ca 
tion. More importantly, the general use of PCR for diagnosis 
is still suspect. Although measures can be taken to improve 
the reliability of PCR, the technique continues to be troubled 
by both false positive and false negative results. 
The selection of an antigen for development of a diag 
nostic test can be someWhat subjective since any particular 
pathogen is composed of numerous antigenic proteins. Logi 
cally, the target molecule in a diagnostic assay must elicit a 
detectable antibody response in the infected animal. In this 
regard, surface antigens of the Coccidia, such as the primary 
surface antigens of Toxoplasma gondii (Handman and Rem 
ington, 1980; Sharma et al., 1983) and Neospora caninum 
(HoWe et al., 1998), are exceedingly inmunogenic. These 
surface antigens have been designated SAGs and SAG 
related sequences (SRSs). Signi?cantly, the TgSAGl sur 
face antigen of T gondii has been shoWn to protect mice 
against acute toxoplasmosis (BuloW and Boothroyd, 1991), 
and the NcSAGl (p29) major surface antigen of N. caninum 
has been used to develop an ELISA for detection of 
Neospora infection in cattle (HoWe et al., 2002). Collec 
tively, these previous studies demonstrate that coccidian 
SAGs are at least candidate proteins for the development of 
both diagnostic assays and protective vaccines. 
Despite the foregoing art, prior to the present invention it 
had not been shoWn that the surface antigens of S. neurona 
(i.e., SnSAG2, SnSAG3, and SnSAG4) are effective target 
molecules for examining immune responses in infected 
horses and for developing improved assays for EPM diag 
nosis. Such molecules Would also provide the basis for 
improved vaccines and diagnostic kits, including antigen 
and antibody kits, for fast and reliable diagnosis of S. 
neurona infection. 
SUMMARY OF THE INVENTION 
The present invention satis?es the aforementioned need in 
the art by providing a novel isolated nucleic acid encoding 
an antigenic protein derived from Sarcocyslis neurona, or a 
unique fragment thereof. In one embodiment, the invention 
provides novel isolated nucleic acids encoding membrane 
associated polypeptides SnSAG2, SnSAG3, and SnSAG4. 
The present invention also provides puri?ed antigenic 
polypeptide fragments encoded by the novel nucleic acid 
sequences set forth herein that encode for Sarcocyslis neu 
rona. In one embodiment, the invention provides puri?ed 
antigenic proteins or puri?ed antigenic polypeptide frag 
ments encoded by the novel nucleic acid sequences set forth 
herein that encode for SnSAG2, SnSAG3, and SnSAG4. In 
another embodiment, the present invention provides a puri 
?ed antigenic polypeptide fragment encoded by the nucleic 
acid sequences set forth herein or a selective portion thereof, 
in a pharmaceutically acceptable carrier. 
The present invention also provides isolated nucleic acids 
capable of selectively hybridizing With the nucleic acid from 
Sarcocyslis neurona including, but not limited to, primers 
and probes for utiliZation in polymerase chain reaction 
US 7,256,282 B2 
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(PCR) and other nucleic acid ampli?cation techniques. The 
isolated nucleic acids of the present invention are capable of 
hybridizing under conditions of loW, moderate, and high 
stringency With a nucleic acid from Sarcocyslis neurona. 
Further, the present invention provides vectors compris 
ing the isolated nucleic acids, or degenerate variants thereof, 
set forth herein encoding Sarcocyslis neurona or a unique 
fragment thereof and provides the vector in a host capable of 
expressing the polypeptide encoded by that nucleic acid. 
Still yet further, the present invention also provides a 
puri?ed polyclonal and or a monoclonal antibody speci? 
cally reactive With Sarcocyslis neurona and a method of 
detection of Sarcocyslis neurona utiliZing the antibodies of 
the present invention. 
The above-described embodiments provided by the 
present invention, provide a method for detecting Sarcocys 
Zis neurona in a biological sample, comprising detecting the 
presence in the sample of an antibody or fragment thereof 
Which speci?cally binds to a polypeptide comprising an 
isolated amino acid sequence selected from the group set 
forth in the Sequence Listing as SEQ ID NO.: 24, SEQ ID 
NO: 26, and SEQ ID NO: 28. In one embodiment of the 
method, the biological sample is serum. In another embodi 
ment, the present invention provides a method as described 
for detecting Sarcocyslis neurona in cerebrospinal ?uid 
(CSF). 
Finally, the present invention provides a kit for detecting 
Sarcocyslis neurona in a biological sample, comprising at 
least one isolated amino acid sequence selected from the 
group set forth in the Sequence Listing as SEQ ID NO.: 24, 
SEQ ID NO: 26, and SEQ ID NO: 28, and a reporter 
molecule for detecting a ?rst antibody or fragment thereof 
Which speci?cally binds to a polypeptide comprising the at 
least one isolated amino acid sequence. The reporter mol 
ecule may be any suitable detectable second antibody or 
fragment thereof Which binds to the ?rst antibody or frag 
ment thereof, and Which is labeled With a detectable moiety 
or bound to a substrate. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a sequence comparison of mature SnSAG1, 
SnSAG3, and SnSAG4 With TgSAG2E. The S. neurona 
surface antigens SnSAG1, SnSAG3 and SnSAG4 are most 
similar to the TgSAG2 family of T gondi surface antigens. 
The sequences presented in the Figure are for the mature 
proteins after cleaving off the N-terminal signal peptide and 
the C-terminal signal for the GPI anchor. Sequence align 
ments of the predicted mature proteins revealed very mod 
erate sequence identity (<25%). HoWever, the SnSAGs 
contain 10/12 conserved cysteine residues that have been 
observed previously, suggesting that the SnSAGs have a 
tertiary structure that is similar to What has been determined 
for the TgSAGs/SRSs. 
FIG. 2 is a sequence comparison of mature SnSAG2 With 
TgSAG1 and TgSRS2. The sequences presented in the 
Figure are for the mature proteins after cleaving off the 
N-terminal signal peptide and the C-terminal signal for the 
GPI anchor. The S. neurona surface antigen SnSAG2 is most 
similar to the TgSAG1 family of T gondii surface antigens. 
Similar to the other SnSAGs, SnSAG2 shares modest 
sequence identity to its TgSAG orthologues, but contains 6/6 
conserved cysteine residues that have been observed in each 
half of the prototypical tWo-domain apicomplexan SAG. 
SnSAG2 Will also align With the carboxyl-terminal domain 
of the TgSAGs. 
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FIG. 3 shoWs a Western blot analysis of the SnSAGs in S. 
neurona meroZoites. The SnSAG genes Were expressed in E. 
coli, and monospeci?c polyclonal antisera Were generated 
against the recombinant proteins. Western blot analysis of 
reduced antigen revealed that each SnSAG migrated signi? 
cantly higher than its predicted molecular Weight, consistent 
With What has been observed for the T gondii SAGs/SRS. 
SnSAG1 and SnSAG4 co-migrated and corresponded to the 
immunodominant band at about 30-32 kDa. SnSAG2 cor 
responded to an immunodominant band at approximately 
18-20 kDa. 
FIG. 4 shoWs the SnSAGs are membrane-associated in 
Sarcocyslis neurona meroZites. Triton X-114 partitioning 
assays indicated that the SnSAGs are associated With mem 
branes, consistent With their surface localiZation via gly 
colipid anchoring. Western blot analysis of the partitioned 
proteins With the SnSAG-speci?c polyclonal antisera 
revealed that all four SnSAGs Were separated exclusively 
into the detergent phase (D). The control protein, SnMIClO, 
Was partitioned into the aqueous phase (A), as expected. 
FIG. 5 shoWs that the four SnSAGs are displayed on the 
surface of Sarcocyslis neurona meroZoites. Surface biotiny 
lation of S. neurona meroZoites indicated that the four 
SnSAGs are displayed on the surface of the parasite. West 
ern blot analysis With the SnSAG-speci?c antisera revealed 
each of the SnSAGs in the biotinylated protein fraction 
precipitated With immobiliZed streptavidin. The SnSAGs 
Were not present in the non-labeled parasites, thus indicating 
that the streptavidin precipitation Were speci?c for biotin 
labeled proteins. The negative control protein (actin) Was not 
detected in the biotin-labeled/streptavidin-precipitated pro 
tein fraction. 
FIG. 6 shoWs reciprocal antibody titers in serum of 
EPM-con?rmed horses, determined by an ELISA using the 
recombinant surface antigens of the present invention. 
FIG. 7 shoWs reciprocal antibody titers in CSF of EPM 
con?rmed horses, determined by an ELISA using the recom 
binant surface antigens of the present invention. 
FIG. 8 shoWs expression of S. neurona surface antigens in 
COS-1 (green monkey kidney) cells, detected by immunof 
luorescent labeling With ?uorescein isothiocyanate. 
DETAILED DESCRIPTION OF THE 
INVENTION 
The present invention may be understood more readily by 
reference to the folloWing detailed description of speci?c 
embodiments and the examples included therein. As used in 
the claims, “a” can mean one or more. As can be appreciated 
by one of skill in the art, methods and materials similar or 
equivalent to those described herein can be used in the 
practice of the present invention. All publications, patent 
applications, patents, and other references mentioned herein 
are incorporated by reference in their entirety in order to 
more fully describe the state of the art to Which this 
invention pertains. It is noted that the abbreviated citations 
of literature referenced herein are set forth fully in US. 
patent application Ser. No. 10/369,430, the disclosure of 
Which is also incorporated herein in its entirety by reference. 
Although the present invention has been described With 
reference to speci?c details of certain embodiments thereof, 
it is not intended that such details should be regarded as 
limitations upon the scope of the invention except as and to 
the extent that they are included in the accompanying 
claims. In the case of a con?ict With incorporated references, 
the present speci?cation, including de?nitions, Will control. 
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In addition, the particular embodiments discussed below are 
illustrative only and not intended to be limiting. 
The present invention satis?es the long felt need in the art 
by providing novel isolated nucleic acid sequences Which 
encode antigenic proteins derived from Sarcocyslis neurona, 
or Which encode unique antigenic protein fragments thereof. 
As used herein, a “nucleic acid” means a chain of at least 
tWo or more nucleotides such as DNA (deoxyribonucleic 
acid) or RNA (ribonucleic acid). As used herein, a “puri?ed” 
nucleic acid is one that is substantially separated from other 
nucleic acid sequences in a cell or organism in Which the 
nucleic acid naturally occurs. Likewise, by “isolated” 
nucleic acid is meant separated from at least some of other 
nucleic acids found in the naturally-occurring organism. The 
nucleic acids of the present invention can include positive 
and negative strand RNA as Well as DNA. The above terms 
encompass double-stranded DNA, single-stranded DNA, 
and RNA and are meant to include genomic and subgenomic 
nucleic acids found in the naturally-occurring Sarcocyslis 
neurona organism. The nucleic acids contemplated by the 
present invention include a nucleic acid having sequences 
from Which a Sarcocyslis neurona cDNA can be transcribed; 
or allelic variants and/or homologs of thereof. By “capable 
of selectively hybridizing” is meant a sequence Which does 
not hybridize With other nucleic acids to prevent an adequate 
positive hybridization With nucleic acids from Sarcocyslis 
neurona and is meant to include stringent hybridization 
conditions including loW, moderate and high stringency 
conditions. Such stringency conditions are knoWn in the art, 
e.g., in US Patent Publication No.: 2002/0115828 A1. By 
“unique fragment” is meant a fragment of the nucleic acids 
set forth in the Sequence Listing that is less than the full 
length that can selectively hybridize With a RNA, DNA or 
cDNA sequence derived from the novel sequences set forth 
herein or that can selectively hybridize With nucleic acids 
from Sarcocyslis neurona. Modi?cations to the nucleic acids 
of the invention are also contemplated as long as the 
essential structure and function of the polypeptide encoded 
by the nucleic acids is maintained. Likewise, fragments used 
as primers or probes can have substitutions so long as 
enough complementary bases exist for selective hybridiza 
tion (Kunkel et al. Methods Enzmol. 1987: 154-367, 1987). 
As one of skill in the art can appreciate, there can be 
naturally occurring allelic variants and non-naturally occur 
ring variants or modi?cations of the nucleic acids of the 
invention. For example, homologs or naturally occurring 
allelic variants of the nucleic acids of the invention having 
from about 50% and up to about 99% sequence identity are 
contemplated by the invention. LikeWise, it is contemplated 
that non-naturally occurring variants or modi?cations of the 
nucleic acids of the invention can range from about 50% to 
about 99% sequence identity to native S. neurona are 
contemplated. 
In particular, one embodiment of the present invention 
provides isolated nucleic acids derived from three Sarco 
cyslis neurona cluster sequences, namely Sn Cluster 144, Sn 
Cluster 21 and Sn Cluster 4, Which comprise the nucleotide 
sequences set forth in the Sequence Listing as SEQ ID NOS: 
1, 3, and 29 respectively and the sequences complimentary 
thereto. Also provided by the invention are the correspond 
ing protein or polypeptide amino acid sequences for these 
three Sarcocyslis neurona cluster sequences. The polypep 
tide sequence comprising Sn Cluster 144 is set forth in the 
Sequence Listing as SEQ ID NO: 2. The polypeptide 
sequence comprising Sn Cluster 21 is set forth in the 
Sequence Listing as SEQ ID NO: 4 and the polypeptide 
sequence comprising Sn Cluster 4 is set forth in the 
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Sequence Listing as SEQ ID NO: 30. As used herein, the 
terms “polypeptide” and “protein” are used interchangeably 
and are meant to include any peptide-linked chain of amino 
acids, regardless of length or post-translational modi?cation, 
e.g., glycosylation or phosphorylation. By “puri?ed” 
polypeptide is meant a polypeptide that has been substan 
tially separated or isolated aWay from other polypeptides in 
a cell, organism, or mixture in Which the polypeptide occurs. 
Similar to other members of the Apicomplexa, S. neurona 
is an obligate intracellular pathogen that utilizes a number of 
unique structures and molecules (i.e., virulence factors) to 
support its parasitic lifestyle. Parasite surface molecules are 
virulence factors that are typically novel and undoubtedly 
important since they are responsible for the initial interac 
tions With the host cell surface and host immune response. 
In Toxoplasma gondii, for example, an extensive family of 
25+ surface antigens has been identi?ed, Which are devel 
opmentally regulated and exhibit various levels of sequence 
similarity to either of the major T gondii surface antigens 
TgSAG1 or TgSAG2. These surface molecules appear to be 
involved in receptor/ligand interactions With the host cell 
surface, and there is increasing evidence that some of the T 
gondii SAGs are involved in modulation of host immune 
responses. 
In one embodiment, the present invention provides iden 
tity and characterization of certain of the virulence factors of 
S. neurona. In particular, the present invention provides four 
isolated nucleic acids of S. neurona (genes) that encode 
parasitic surface antigens. A sequencing project Was con 
ducted that generated approximately 8500 expressed 
sequence tags (ESTs) from this organism. Examination of 
this sequence database has revealed a family of at least four 
S. neurona surface antigens that are orthologues of the 
SAG/SRS family of surface proteins in T gondii. Each 
protein is predicted to contain an amino-terminal signal 
peptide and a carboxyl-terminal glycolipid anchor addition 
site, indicating surface localization, and Triton X-114 par 
titioning and surface biotinylation assays con?rmed that all 
four proteins are membrane-associated and displayed on the 
S. neurona merozoite surface (See, FIGS. 4 and 5). Addi 
tionally, these novel S. neurona proteins possess multiple 
conserved cysteine residues that have been described pre 
viously for T gondii SAGs and Which are likely important 
for the tertiary structure of the proteins (See, FIGS. 1 and 2). 
Due to their surface localization and relative homology to T 
gondii surface antigens, these S. neurona proteins have been 
designated SnSAG1, SnSAG2, SnSAG3, and SnSAG4. 
Accordingly, one embodiment of the present invention 
comprises an isolated nucleic acid as set forth in the 
Sequence listing as SEQ ID NO: 21. The nucleic acid 
identi?ed in SEQ ID NO: 21 comprises an 828-nucleotide 
open reading frame of the SnSAGl gene of Sarcocyslis 
neurona Which encodes a 276 amino acid polypeptide set 
forth in the Sequence Listing as SEQ ID NO: 22. The 
polypeptide encoded by SEQ ID NO: 22 has a predicted 
amino-terminal signal peptide (indicating expression via the 
secretory pathWay) and a glycolipid anchor addition site at 
the carboxy-terminal end (indicating surface localization). 
Database searches With the predicted protein sequence of 
SnSAGl (rSnSAGl) revealed signi?cant similarity (align 
ment score:80, E value:2><10—14) to a 31 kDa surface 
antigen from Sarcocyslis muris. 
A recombinant form of the Sarcocyslis neurona SnSAGl 
(rSnSAGl) has been expressed in E. coli. Western blot 
analysis of rSnSAGl demonstrated that the recombinant 
antigen is recognized by antiserum from a rabbit that Was 
immunized With S. neurona merozoites and by antibodies in 
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cerebrospinal ?uid (CSF) from an EPM (Sarcocyslis neu 
rona infected) horse (See, e.g., FIG. 3). 
Another embodiment of the present invention comprises 
an isolated nucleic acid as set forth in the Sequence listing 
as SEQ ID NO: 23. The nucleic acid identi?ed in SEQ ID 
NO: 23 comprises an 975 nucleotide open reading frame of 
the SnSAG2 gene of Sarcocyslis neurona Which encodes a 
168 amino acid polypeptide set forth in the Sequence Listing 
as SEQ ID NO: 24. 
The present invention also provides an isolated nucleic 
acid as set forth in the Sequence listing as SEQ ID NO: 25. 
The nucleic acid identi?ed in SEQ ID NO: 25 comprises an 
1585 nucleotide open reading frame of the SnSAG3 gene of 
Sarcocyslis neurona Which encodes a 281 amino acid 
polypeptide set forth in the Sequence Listing as SEQ ID NO: 
26. 
Also provided by the present invention is an isolated 
nucleic acid as set forth in the Sequence listing as SEQ ID 
NO: 27. The nucleic acid identi?ed in SEQ ID NO: 27 
comprises an 1111 nucleotide open reading frame of the 
SnSAG4 gene of Sarcocyslis neurona Which encodes a 287 
amino acid polypeptide set forth in the Sequence Listing as 
SEQ ID NO: 28. 
As set forth more fully beloW, these genes have been 
expressed as recombinant proteins in E. coli. The recombi 
nant SnSAG proteins can be implemented into antibody 
capture ELISAs and used to detect the presence of S. 
neurona antibodies in a sample. Likewise, the recombinant 
proteins provided by the invention can be used as reagents 
for use in vaccines against S. neurona. 
Another embodiment of the present invention includes the 
discovery of additional novel expressed sequence tags (EST) 
that encode novel antigenic peptides for utiliZation in the 
vaccines and diagnostic kits as disclosed by this invention. 
In particular, cluster analysis of the Sarcocyslis neurona 
expressed sequence tags (ESTs) generated from the cSn.l 
cDNA library has revealed a gene family that encodes at 
least eight homologous proteins. Of the approximately 8500 
S. neurona ESTs that have been generated thus far, roughly 
540 sequences can be placed in this gene family, Which has 
been provisionally designated SnGFl (S. neurona Gene 
Family 1). Based on its relative abundance in the collection 
of S. neurona ESTs, SnGFl encodes a set of similar proteins 
(at least eight) that are highly expressed and most likely play 
signi?cant roles in the biology of S. neurona (i.e., parasite 
virulence factors). In addition to their biological importance, 
the abundance of these proteins Would suggest that they 
elicit signi?cant immune responses in infected animals. 
Collectively, the characteristics of the novel nucleic acids of 
SnGFl, and the encoded proteins therefrom, make this gene 
family Well suited for the development of improved diag 
nostics and/or vaccines for EPM as set forth herein. 
The eight SnGFl isoforms identi?ed thus far have been 
designated SnGFla-h. These genes are predicted to encode 
proteins of, e.g., 109 amino acids, 106 amino acids, and 107 
amino acids in length, and the proteins share approximately 
70% to 80% sequence identity. These proteins have a 
predicted N-terminal signal peptide and a predicted trans 
membrane domain near the C-terminus. The SnGFl mem 
bers shoW no similarity to sequences in the current public 
gene databases, suggesting that SnGFl is relatively unique 
to S. neurona. 
Accordingly, one embodiment of the present invention 
provides an isolated nucleic acid designated SnGFla Which 
comprises the nucleic acid set forth in SEQ ID NO: 5 and 
sequences complimentary thereto. Another embodiment of 
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the invention comprises the polypeptide sequence encoded 
by SnGFla set forth in the Sequence Listing as SEQ ID NO: 
6. 
Another embodiment of the present invention provides an 
isolated nucleic acid designated SnGFlb Which comprises 
the nucleic acid set forth in SEQ ID NO: 7 and sequences 
complimentary thereto. Another embodiment of the inven 
tion comprises the polypeptide sequence encoded by 
SnGFlb set forth in the Sequence Listing as SEQ ID NO: 8. 
Yet another embodiment of the present invention provides 
an isolated nucleic acid designated SnGFlc Which com 
prises the nucleic acid set forth in SEQ ID NO: 9 and 
sequences complimentary thereto. Another embodiment of 
the invention comprises the polypeptide sequence encoded 
by SnGFlc set forth in the Sequence Listing as SEQ ID NO: 
10. 
Still another embodiment of the present invention pro 
vides an isolated nucleic acid designated SnGFld Which 
comprises the nucleic acid set forth in SEQ ID NO: 11 and 
sequences complimentary thereto. Another embodiment of 
the invention comprises the polypeptide sequence encoded 
by SnGFld set forth in the Sequence Listing as SEQ ID NO: 
12. 
The present invention also provides an isolated nucleic 
acid designated SnGFle Which comprises the nucleic acid 
set forth in SEQ ID NO: 13 and sequences complimentary 
thereto. Another embodiment of the invention comprises the 
polypeptide sequence encoded by SnGFle set forth in the 
Sequence Listing as SEQ ID NO: 14. 
Another embodiment of the present invention provides an 
isolated nucleic acid designated SnGFlf Which comprises 
the nucleic acid set forth in SEQ ID NO: 15 and sequences 
complimentary thereto. Another embodiment of the inven 
tion comprises the polypeptide sequence encoded by 
SnGFlf set forth in the Sequence Listing as SEQ ID NO: 16. 
Yet another embodiment of the present invention provides 
an isolated nucleic acid designated SnGFl g Which com 
prises the nucleic acid set forth in SEQ ID NO: 17 and 
sequences complimentary thereto. Another embodiment of 
the invention comprises the polypeptide sequence encoded 
by SnGFl g set forth in the Sequence Listing as SEQ ID NO: 
18. 
Still another embodiment of the present invention pro 
vides an isolated nucleic acid designated SnGFl h Which 
comprises the nucleic acid set forth in SEQ ID NO: 19 and 
sequences complimentary thereto. Another embodiment of 
the invention comprises the polypeptide sequence encoded 
by SnGFl h set forth in the Sequence Listing as SEQ ID NO: 
20. 
The present invention provides isolated nucleic acids as 
set forth in the Sequence Listing and nucleic acid reagents 
derived therefrom Which can be utiliZed to diagnose and 
prevent infection of S. neurona. Puri?ed polypeptides 
encoded by the nucleic acids are also provided. These 
polypeptides can be utiliZed in methods of diagnosis or as 
vaccine components for prevention of infection. Vectors are 
also provided Which comprise the nucleic acids of the 
present invention. The vectors can be utiliZed in host expres 
sion systems to produce antigenic peptide reagents for 
diagnostic and prophylactic applications. The present inven 
tion also provides puri?ed antibodies selectively reactive 
With S. neurona. These antibodies can be used in various 
diagnostic methods or as a therapeutic. 
In one embodiment, the invention provides puri?ed anti 
genic polypeptides encoded by the nucleic acids set forth in 
the Sequence Listing. The invention also provides these 
antigenic polypeptides in a pharmaceutically acceptable 
US 7,256,282 B2 
carrier. The amino acid sequence of these polypeptides can 
be deduced from the nucleotide sequences set forth in the 
Sequence Listing. 
Puri?ed antigenic polypeptide fragments encoded by the 
nucleic acids of the present invention are also contemplated. 
As used herein, “puri?ed” means the antigen is at least 
su?iciently free of contaminants or cell components With 
Which the antigen normally occurs to distinguish the antigen 
from the contaminants or components. Puri?ed antigenic 
polypeptides of S. neurona and antigenic fragments thereof 
of the present invention are also referred to herein as “the 
antigen” or “the S. neurona antigen.” It is contemplated that 
the antigenic fragments can be encoded from any portion of 
the nucleic acid encoding S. neurona as set forth in the 
Sequence Listing, but especially-from fragments encoded by 
the open reading frames set forth in SEQ ID NOS: 24, 26 
and 28 as described herein. Speci?cally, one example pro 
vides an approximately 12 kDa antigenic polypeptide 
encoded by an open reading frame of SEQ ID NO: 24 
consisting essentially of the amino acids encoded by the 
nucleotide as sequence set forth in the Sequence Listing as 
SEQ ID NO: 23. 
An antigenic fragment of the antigen can be isolated from 
the Whole antigen by chemical or mechanical disruption. 
The puri?ed fragments thus obtained can be tested to 
determine their antigenicity and speci?city by the methods 
taught herein. Antigenic fragments of the antigen can also be 
synthesiZed directly. An immunoreactive fragment is gen 
erally an amino acid sequence of at least about ?ve con 
secutive amino acids derived from the antigen amino acid 
sequence. 
The polypeptide fragments of the present invention can 
also be recombinant proteins obtained by cloning nucleic 
acids encoding the polypeptide in an expression system 
capable of producing the antigenic polypeptide or fragments 
thereof. 
Once the amino acid sequence of the antigen is provided, 
it is also possible to synthesiZe, using standard peptide 
synthesis techniques, peptide fragments chosen to be 
homologous to immunoreactive regions of the antigen and to 
modify these fragments by inclusion, deletion or modi?ca 
tion of particular amino acids residues in the derived 
sequences. Thus, synthesis or puri?cation of an extremely 
large number of peptides derived from the antigen is pos 
sible. 
The amino acid sequences of the present polypeptides can 
contain an immunoreactive portion of the S. neurona antigen 
attached to sequences designed to provide for some addi 
tional property, such as solubility. The amino acid sequences 
of an S. neurona antigen can include sequences in Which one 
or more amino acids have been substituted With another 
amino acid to provide for some additional property, such as 
to remove/add amino acids capable of disul?de bonding, to 
increase its bio-longevity, alter enzymatic activity, or alter 
interactions, e.g., With gastric acidity. In any case, the 
peptide should posses a bioactive property, such as immu 
noreactivity, immunogenicity, etc. 
The puri?ed polypeptide fragments thus obtained can be 
tested to determine their immunogenicity and speci?city. 
Brie?y, various concentrations of a putative immunogeni 
cally speci?c fragment are prepared and administered to an 
animal and the immunological response (e.g., the production 
of antibodies or cell mediated immunity) of an animal to 
each concentration is determined. The amounts of antigen 
administered depend on the subject, eg a horse or a guinea 
pig, the condition of the subject, the siZe of the subject, etc. 
Thereafter an animal so inoculated With the antigen can be 
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exposed to the parasite to test the potential vaccine effect of 
the speci?c immunogenic fragment. The speci?city of a 
putative immunogenic fragment can be ascertained by test 
ing sera, other ?uids or lymphocytes from the inoculated 
animal for cross reactivity With other closely related Sarco 
cyslis spp. 
A vector comprising the nucleic acids of the present 
invention is also provided. The vectors of the invention can 
be in a host capable of expressing the antigenic polypeptide 
fragments contemplated by the present invention. There are 
numerous E. coli expression vectors knoWn to one of 
ordinary skill in the art useful for the expression of the 
antigen. Other microbial hosts suitable for use include 
bacilli, such as Bacillus sublilis, and other enlerobacleri 
aceae, such as Salmonella, Serralia, and various Pseudomo 
nas species. In these prokaryotic hosts one can also make 
expression vectors, Which Will typically contain expression 
control sequences compatible With the host cell (e.g., an 
origin of replication). In addition, any number of a variety of 
Well-known promoters can be present, such as the lactose 
promoter system, a tryptophan (Trp) promoter system, a 
beta-lactamase promoter system, or a promoter system from 
phage lambda. The promoters Will typically control expres 
sion, optionally With an operator sequence, and have ribo 
some binding site sequences for example, for initiating and 
completing transcription and translation. If necessary, for 
example, an amino terminal methionine can be provided by 
insertion of a Met codon 5' and in-frame With the antigen. 
Also, the carboxyterrniinal extension of the antigenic frag 
ments can be removed using standard oligonucleotide 
mutagenesis procedures. 
Additionally, yeast expression can be used. There are 
several advantages to yeast expression systems. First, evi 
dence exists that proteins produced in a yeast secretion 
systems exhibit correct disul?de pairing. Second, post 
translational glycosylation is ef?ciently carried out by yeast 
secretory systems. In one example, the Saccharomyces cer 
evisiae pre-pro-alpha-factor leader region (encoded by the 
MF.alpha.-l gene) is routinely used to direct protein secre 
tion from yeast (Brake et al.,l984). The leader region of 
pre-pro-alpha-factor contains a signal peptide and a pro 
segment Which includes a recognition sequence for a yeast 
protease encoded by the KEX2 gene: this enZyme cleaves 
the precursor protein on the carboxyl side of a Lys-Arg 
dipeptide cleavage-signal sequence. The antigen coding 
sequence can be fused in-frame to the pre-pro-alpha-factor 
leader region. This construct is then put under the control of 
a strong transcription promoter, such as the alcohol dehy 
drogenase I promoter or a glycolytic promoter. The antigen 
coding sequence is folloWed by a translation termination 
codon Which is folloWed by transcription termination sig 
nals. Alternatively, the antigen coding sequences can be 
fused to a second protein coding sequence, such as Sj26 or 
.beta.-galactosidase, used to facilitate puri?cation of the 
fusion protein by af?nity chromatography. The insertion of 
protease cleavage sites to separate the components of the 
fusion protein is applicable to constructs used for expression 
in yeast. 
Mammalian cells permit the expression of proteins in an 
environment that favors important post-translational modi 
?cations such as folding and cysteine pairing, addition of 
complex carbohydrate structures, and secretion of active 
protein. Vectors useful for the expression of antigen in 
mammalian cells are characterized by insertion of the anti 
gen coding sequence betWeen a strong viral promoter and a 
polyadenylation signal. The vectors can contain genes con 
ferring either gentamicin or methotrexate resistance for use 
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as selectable markers. The antigen and immunoreactive 
fragment coding sequence can be introduced into a Chinese 
hamster ovary cell line using a methotrexate resistance 
encoding vector. Presence of the vector DNA in transformed 
cells can be con?rmed by Southern analysis and production 
of a cDNA or opposite strand RNA corresponding to the 
antigen coding sequence can be con?rmed by northern 
analysis. A number of other suitable host cell lines capable 
of secreting intact proteins have been developed in the art, 
and include the CHO cell lines, HeLa cells, myeloma cell 
lines, Jurkat cells, etc. Expression vectors for these cells can 
include expression control sequences, such as an origin of 
replication, a promoter, an enhancer, and necessary infor 
mation processing sites, such as ribosome binding sites, 
RNA splice sites, polyadenylation sites, and transcriptional 
terminator sequences. Preferred expression control 
sequences are promoters derived from immunoglobulin 
genes, SV40, Adenovirus, Bovine Papilloma Virus, etc. The 
vectors containing the nucleic acid segments of interest can 
be transferred into the host cell by Well-knoWn methods, 
Which vary depending on the type of cellular host. For 
example, calcium chloride transfection is commonly utilized 
for prokaryotic cells, Whereas calcium phosphate treatment 
or electroporation may be used for other celluar hosts. 
Alternative vectors for the expression of antigen in mam 
malian cells can be employed, similar to those developed for 
the expression of human gammainterferon, tissue plasmino 
gen activator, clotting Factor VIII, hepatitis B virus surface 
antigen, protease Nexinl, and eosinophil major basic protein. 
Further, the vector can include CMV promoter sequences 
and a polyadenylation signal available for expression of 
inserted nucleic acid in mammalian cells (such as COS7). 
The nucleic acid sequences can be expressed in hosts after 
the sequences have been operably linked to, i.e., positioned 
to ensure the functioning of, an expression control sequence. 
These expression vectors are typically replicable in the host 
organisms either as episomes or as an integral part of the 
host chromosomal DNA. Commonly, expression vectors can 
contain selection markers, e.g., tetracycline resistance or 
hygromycin resistance, to pennit detection and/or selection 
of those cells transformed With the desired nucleic acid 
sequences (see, e.g., US. Pat. No. 4,704,362). 
Polynucleotides encoding a variant polypeptide may 
include sequences that facilitate transcription (expression 
sequences) and translation of the coding sequences such that 
the encoded polypeptide product is produced. Construction 
of such polynucleotides is Well knoWn in the art. For 
example, such polynucleotides can include a promoter, a 
transcription termination site (polyadenylation site in 
eukaryotic expression, hosts), a ribosome binding site, and, 
optionally, an enhancer for use in eukaryotic expression 
hosts, and, optionally, sequences necessary for replication of 
a vector. 
One presently preferred vector system for expression of 
the peptides of the invention comprises the use of Alphavi 
rus vector constructs, for example, as set forth in US. Pat. 
Nos. 5,643,576; 5,843,723; 6,156,558; and 6,242,259, the 
teachings of Which are hereby incorporated herein by ref 
erence. 
A puri?ed monoclonal antibody speci?cally reactive With 
S. neurona is also provided. The antibodies can be speci? 
cally reactive With a unique epitope of the antigen or they 
can also react With epitopes of other organisms. The term 
“reactive” means capable of binding or otherWise associat 
ing non randomly With an antigen. “Speci?cally reactive” as 
used herein refers to an antibody or other ligand that does 
not cross react substantially With any antigen other than the 
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one speci?ed, in this case, S. neurona. Antibodies can be 
made as described in the Examples (see also, HarloW and 
Lane, Antibodies; A Laboratory Manual, Cold Spring Har 
bor Laboratory, Cold Spring Harbor, N.Y., 1988). Brie?y 
puri?ed antigen can be injected into an animal in an amount 
and in intervals sufficient to elicit an immune response. 
Antibodies can either be puri?ed directly, or spleen cells can 
be obtained from the animal. The cells are then fused With 
an immortal cell line and screened for antibody secretion. 
The antibodies can be used to screen clone libraries for cells 
secreting the antigen. Those positive clones can then be 
sequenced (see, for example, Kelly et al., Bio/Technology, 
10: 163-167, (1992) and Bebbington et at., Bio/Technology, 
10: 169-175, (1992). 
The antibody can be bound to a substrate or labeled With 
a detectable moiety or both bound and labeled. The detect 
able moieties contemplated by the present invention include, 
but are not limited to ?uorescent, enzymatic and radioactive 
markers. 
A puri?ed S. neurona antigen bound to a substrate and a 
ligand speci?cally reactive With the antigen are also con 
templated. Such a puri?ed ligand speci?cally reactive With 
the antigen can be an antibody. The antibody can be a 
monoclonal antibody obtained by standard methods and as 
described herein. The monoclonal antibody can be secreted 
by a hybridoma cell line speci?cally produced for that 
purpose (HarloW and Lane, 1988). Likewise, nonhuman 
polyclonal antibodies speci?cally reactive With the antigen 
are Within the scope of the present invention. The polyclonal 
antibody can also be obtained by the standard immunization 
and puri?cation protocols (HarloW and Lane, 1988). 
The present invention provides a method of detecting the 
presence of S. neurona in a subject, comprising the steps of 
contacting an antibody-containing sample from the subject 
With a detectable amount of the antigenic polypeptide frag 
ment of the present invention and detecting the reaction of 
the fragment and the antibody, the reaction indicating the 
presence of the S. neurona or a previous infection With S. 
neurona. 
One example of the method of detecting S. neurona is 
performed by contacting a ?uid or tissue sample from the 
subject With an amount of a puri?ed antibody speci?cally 
reactive With the antigen as de?ned herein, and detecting the 
reaction of the ligand With the antigen. It is contemplated 
that the antigen Will be on intact cells containing the antigen, 
or Will be fragments of the antigen. As contemplated herein, 
the antibody includes any ligand Which binds the antigen, for 
example, an intact antibody, a fragment of an antibody or 
another reagent that has reactivity With the antigen. The ?uid 
sample of this method can comprise any body ?uid Which 
Would contain the antigen or a cell containing the antigen, 
such as blood, plasma, serum, cerebrospinal ?uid, saliva, 
feces and urine. Other possible examples of body ?uids 
include sputum, mucus, gastric juice and the like. 
Enzyme immunoassays such as immuno?uorescence 
assays (IFA), enzyme linked immunosorbent assays 
(ELISA) and immunoblotting can be readily adapted to 
accomplish the detection of the antigen. An ELISA method 
effective for the detection of the antigen can, for example, be 
as folloWs: (1) bind the antibody to a substrate; (2) contact 
the bound antibody With a ?uid or tissue sample containing 
the antigen; (3) contact the above With a secondary antibody 
bound to a detectable moiety (e.g., horseradish peroxidase 
enzyme or alkaline phosphatase enzyme); (4) contact the 
above With the substrate for the enzyme; (5) contact the 
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above With a color reagent; (6) observe color change. The 
above method can be readily modi?ed to detect antibody as 
Well as antigen. 
Another immunologic technique that can be useful in the 
detection of S. neurona or previous S. neurona infection 
utiliZes monoclonal antibodies (MAbs) for detection of 
antibodies speci?cally reactive With S. neurona antigen. 
Brie?y, sera or other body ?uids from the subject is reacted 
With the antigen bound to a substrate (e. g. an ELISA 96-Well 
plate). Excess sera is thoroughly Washed aWay. A labeled 
(enzyme-linked, ?uorescent, radioactive, etc.) monoclonal 
antibody is then reacted With the previously reacted antigen 
serum antibody complex. The amount of inhibition of mono 
clonal antibody binding is measured relative to a control (no 
patient serum antibody). The degree of monoclonal antibody 
inhibition is a very speci?c test for a particular variety or 
strain since it is based on monoclonal antibody binding 
speci?city. MAbs can also be used for detection directly in 
cells by IFA. 
A micro-agglutination test can also be used to detect the 
presence of S. neurona in a subject. Brie?y, latex beads (or 
red blood cells) are coated With the antigen and mixed With 
a sample from the subject, such that antibodies in the tissue 
or body ?uids that are speci?cally reactive With the antigen 
crosslink With the antigen, causing agglutination. The agglu 
tinated antigen-antibody complexes form a precipitate, vis 
ible With the naked eye or capable of being detected by a 
spectrophotometer. In a modi?cation of the above test, 
antibodies speci?cally reactive With the antigen can be 
bound to the beads and antigen in the tissue or body ?uid 
thereby detected. 
In addition, as in a typical sandwich assay, the antibody 
can be bound to a substrate and reacted With the antigen. 
Thereafter, a secondary labeled antibody is bound to 
epitopes not recogniZed by the ?rst antibody and the sec 
ondary antibody is detected. Since the present invention 
provides S. neurona antigen for the detection of infectious, 
S. neurona or previous S. neurona infection other serological 
methods such as ?oW cytometry and immunoprecipitation 
can also be used as detection methods. 
In the diagnostic methods taught herein, the antigen can 
be bound to a substrate and contacted by a ?uid sample such 
as serum, cerebrospinal ?uid, urine, saliva, feces or gastric 
juice. This sample can be taken directly from the patient or 
in a partially puri?ed form. In this manner, antibodies 
speci?c for the antigen (the primary antibody) Will speci? 
cally react With the bound antigen. Thereafter, a secondary 
antibody bound to, or labeled With, a detectable moiety can 
be added to enhance the detection of the primary antibody. 
Generally, the secondary antibody or other ligand Which is 
reactive, either speci?cally With a different epitope of the 
antigen or nonspeci?c ally With, the ligand or reacted 
antibody, Will be selected for its ability to react With multiple 
sites on the primary antibody. Thus, for example, several 
molecules of the secondary antibody can react With each 
primary antibody, making the primary antibody more detect 
able. 
The detectable moiety Will alloW visual detection of a 
precipitate or a color change, visual detection by micros 
copy, or automated detection by spectrometry, radiometric 
measurement or the like. Examples of detectable moieties 
include ?uorescein and rhodamine (for ?uorescence micros 
copy), horseradish peroxidase (for either light or electron 
microscopy and biochemical detection), biotin-streptavidin 
(for light or electron incroscopy) and alkaline phosphatase 
(for biochemical detection by color change). The detection 
methods and moieties used can be selected, for example, 
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from the list above or other suitable examples by the 
standard criteria applied to such selections (HarloW and 
Lane, 1988). 
The antigen, e.g., a puri?ed antigenic polypeptide frag 
ment encoded by the Sequence Listing of this invention can 
be used in the construction of a vaccme comprising an 
immunogenic mount of the antigen and a pharmaceutically 
acceptable carrier. The vaccine can be the entire antigen, the 
antigen on an intact S. neurona organism, E. coli or other 
strain, or an epitope speci?c to the antigen. The vaccine can 
also be potentially cross-reactive With antibodies to other 
antigens. The vaccine can then be used in a method of 
preventing EPM or other complications of S. neurona infec 
tion. 
Immunogenic amounts of the antigen can be determined 
using standard procedures. Brie?y, various concentrations of 
a putative speci?c immunoreactive epitope are prepared, 
administered to an animal and the immunological response 
(e.g., the production of antibodies) of an animal to each 
concentration is determined. 
The pharmaceutically acceptable carrier can comprise 
saline or other suitable carriers (Arnon, R. (Ed.) Synthetic 
Vaccines I: 83-92, CRC Press, Inc., Boca Raton, Fla., 1987). 
An adjuvant can also be a part of the carrier of the vaccine, 
in Which case it can be selected by standard criteria based on 
the antigen used, the mode of administration and the subject 
(Arnon, R. (Ed.), 1987). Methods of administration can be 
by oral or sublingual means, or by injection, depending on 
the particular vaccine used and the subject to Whom it is 
administered. 
It can be appreciated from the above that the vaccine can 
be used as a prophylactic or a therapeutic modality. Thus, the 
invention provides methods of preventing or treating S. 
neurona infection and the associated diseases by adminis 
tering the vaccine to a subject. 
Nucleic acid vaccines against S. neurona are also con 
templated by the invention. The antigenic agent for use in 
the vaccines of the invention can be any nucleic acid, e.g., 
as set forth in the Sequence Listing, that can stimulate an 
immune response against, e.g., SnSAG2, SnSAG3 or 
SnSAG4 When administered to a subject. Suitable nucleic 
acids include those that encode the native proteins of S. 
neurona, e.g., SnSAG2, SnSAG3 or SnSAG4 protein or a 
variant or antigenic peptide fragment thereof., such as, e.g., 
the nucleic acid set forth in the Sequence listing as SEQ ID 
NO:23, SEQ ID NO:25 or SEQ ID NO:27. The nucleic acid 
used as a vaccine can be e.g., a naked DNA, or the nucleic 
acid can be incorporated in an expression vector as set forth 
herein, e.g., in an Alpha virus vector (see, e.g., Rosenberg, 
S. A., Immunity 10:281, 1999). 
The presence of S. neurona can also be determined by 
detecting the presence of a nucleic acid speci?c for S. 
neurona or the antigens of S. neurona encoded by the nucleic 
acids set forth herein. The present invention provides a 
method of detecting the presence of S. neurona in a subject, 
comprising detecting the presence of the nucleic acid encod 
ing an S. neurona antigen. As set forth more fully in the 
examples beloW, the speci?city of these sequences for S. 
neurona can be determined by conducting a computeriZed 
comparison With knoWn sequences, catalogued in GenBank, 
a computeriZed database, using the computer programs 
Word Search or FASTA of the Genetics Computer Group 
(Madison, Wis.), Which search the catalogued nucleotide 
sequences for similarities to the nucleic acid in question. 
The nucleic acid speci?c for S. neurona antigen can be 
detected utiliZing a nucleic acid ampli?cation technique, 
such as polymerase chain reaction or ligase chain reaction. 
US 7,256,282 B2 
15 
Alternatively, the nucleic acid is detected utilizing direct 
hybridization or by utilizing a restriction fragment length 
polymorphism. For example, the present invention provides 
a method of detecting the presence of S. neurona comprising 
ascertaining the presence of a nucleotide sequence associ 
ated With a restriction endonuclease cleavage site. In addi 
tion, PCR primers Which hybridize only With nucleic acids 
speci?c for S. neurona can be utilized. The presence of 
ampli?cation indicates the presence of S. neurona sequence. 
In another embodiment a restriction fragment of a nucleic 
acid sample can be sequenced directly using, techniques 
knoWn in the art and described herein and compared to the 
knoWn unique sequence to detect S. neurona. In a further 
embodiment, the present invention provides a method of 
detecting the presence of S. neurona by selective ampli? 
cation by the methods described herein. In yet another 
embodiment S. neurona can be detected by directly hybrid 
izing the unique sequence With a S. neurona selective 
nucleic acid probe. Furthermore, the nucleotide sequence 
could be ampli?ed prior to hybridization by the methods 
described above. 
Alternative probing techniques, such as ligase chain reac 
tion (LCR), involve the use of mismatch probes, i.e., probes 
Which are fully complementary With the target except at the 
point of the mutation. The target sequence is then alloWed to 
hybridize both With oligonucleotides Which are fully 
complementary and have oligonucleotides containing a mis 
match, under conditions Which Will distinguish betWeen the 
tWo. By manipulating the reaction conditions, it is possible 
to obtain hybridization only Where there is full complemen 
tarity. If a mismatch is present there is signi?cantly reduced 
hybridization. 
The polymerase chain reaction (PCR) and reverse tran 
scriptase PCR are techniques that amplify speci?c nucleic 
acid sequences With remarkable e?iciency. Repeated cycles 
of denaturation, primer annealing and extension carried out 
With polymerase; e.g., a heat stable enzyme Taq polymerase, 
leads to exponential increases in the concentration of desired 
nucleic acid sequences. Given a knowledge of the nucleotide 
sequence of S. neurona as set forth herein, synthetic oligo 
nucleotides can be prepared Which are complementary to 
sequences Which ?ank the nucleic acid of interest. Each 
oligonucleotide is complementary to one of the tWo strands. 
The nucleic acid can be denatured at high temperatures (e.g., 
95.degree. C.) and then reannealed in the presence of a large 
molar excess of oligonucleotides. The oligonucleotides, 
oriented With their 3' ends pointing toWards each other, 
hybridize to opposite strands of the target sequence and 
prime enzymatic extension along the nucleic acid template. 
The end product is then denatured again for another cycle. 
After this three-step cycle has been repeated several times, 
ampli?cation of a nucleic acid segment by more than one 
million-fold can be achieved. The resulting nucleic acid may 
then be directly sequenced. 
In yet another method, PCR may be folloWed by restric 
tion endonuclease digestion With subsequent analysis of the 
resultant products. Nucleotide substitutions can result in the 
gain or loss of speci?c restriction endonuclease sites. The 
gain or loss of a restriction endonuclease recognition site 
facilitates the detection of the organism using restriction 
fragment length polymorphism (RFLP) analysis or by detec 
tion of the presence or absence of a polymorphic restriction 
endonuclease site in a PCR product that spans the sequence 
of interest. 
For RFLP analysis, nucleic acid is obtained, for example 
from the blood, cerebrospinal ?uid, gastric specimen, saliva, 
dental plaque, other bodily ?uids of the subject suspected of 
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containing S. neurona, is digested With a restriction endo 
nuclease, and subsequently separated on the basis of size by 
agarose gel electrophoresis. The Southern blot technique can 
then be used to detect, by hybridization With labeled probes, 
the products of endonuclease digestion. The patterns 
obtained from the Southern blot can then be compared. 
Using such an approach, S. neurona nucleic acid is detected 
and their mobility on the gel by determining the number of 
bands detected and comparing this pattern to the nucleic acid 
from S. neurona. 
Similar creation of additional restriction sites by nucle 
otide substitutions at the disclosed mutation sites can be 
readily calculated by reference to the genetic code and a list 
of nucleotide sequences recognized by restriction endonu 
cleases. Single strand conformational analysis (SSCA) 
offers a relatively quick method of detecting sequence 
changes Which may be appropriate in at least some 
instances. 
In general, primers for PCR and LCR are usually about 20 
bp in length and the preferable range is from 15-25 hp. 
Better ampli?cation is obtained When both primers are the 
same length and With roughly the same nucleotide compo 
sition. Denaturation of strands usually takes place at about 
94.degree. C. and extension from the primers is usually at 
about 72.degree. C. The annealing temperature varies 
according to the sequence under investigation. Examples of 
reaction times are: 20 mins denaturing; 35 cycles of 2 min, 
1 min, 1 min for annealing, extension and denaturation; and 
?nally a 5 min extension step. 
PCR ampli?cation of speci?c alleles (PASA) is a rapid 
method of detecting single-base mutations or polymor 
phisms. PASA (also knoWn as allele speci?c ampli?cation) 
involves ampli?cation With tWo oligonucleotide primers 
such that one is allele-speci?c. The desired allele is e?i 
ciently ampli?ed, While the other allele(s) is poorly ampli 
?ed because it mismatches With a base at or near the 3' end 
of the allele-speci?c primer. Thus, PASA or the related 
method of PAMSA may be used to speci?cally amplify the 
mutation sequences of the invention. Where such ampli? 
cation is done on S. neurona isolates or samples obtained 
from an individual, it can serve as a method of detecting the 
presence of S. neurona. As mentioned above, a method 
knoWn as ligase chain reaction (LCR) can be used to 
successfully detect a single-base substitution. LCR probes 
may be combined or multiplexed for simultaneously screen 
ing for multiple different mutations. Thus, LCR can be 
particularly useful Where, as here, multiple mutations are 
predictive of the same disease. 
The present invention is more particularly described in the 
folloWing examples Which are intended as illustrative only, 
since numerous modi?cations and variations therein Will be 
apparent to those skilled in the art. 
EXAMPLES 
Identi?cation and Characterization of SnSAGl 
Surface biotinylation of extracellular merozoites revealed 
only tWo dominant labeled molecules that migrate at about 
30 kDa and 16 kDa in SDS-PAGE. Analysis of a S. neurona 
EST database (currently 1800+ sequences) identi?ed an 
orthologue of the 31-kDa surface antigen from Sarcocyslis 
muris. The sequence of the S. neurona surface antigen gene, 
designated SnSAGl, is predicted to encode a 276-residue 
protein With an amino-terminal signal peptide and a car 
boxy-terminal GPI anchor addition. Antiserum raised 
against recombinant SnSAGl recognized a 25-kDa antigen 
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in Western blots of non-reduced S. neurona lysates, consis 
tent With the molecular Weight predicted for the mature 
SnSAGl. Under reducing conditions, SnSAGl migrated 
aberrantly at about 30 kDa, similar to What has been 
observed in Western blot analyses of reduced T gondii 
surface antigens. lmmuno?uorescence labeling of SnSAGl 
during intracellular groWth of S. neurona indicated that the 
protein is expressed throughout schiZogony. Interestingly, a 
?lamentous staining pattern Was observed in intermediate 
schiZonts that likely re?ects localiZation of the surface 
antigen to previously-described invaginations of the sch 
iZont surface membrane. 
Parasite Culture 
S. neurona strain SN3 [Granstrom, 1992 #1600] mero 
Zoites Were propagated by serial passage in bovine turbinate 
(BT) cells and maintained in RPMI 1640 medium supple 
mented With 10% fetal bovine serum, 2 mM sodium pyru 
vate, Pen/Strep FungiZone (BioWhittaker, Inc.). Extracellu 
lar meroZoites Were harvested and puri?ed from disrupted 
host cell monolayers by ?ltration through 3.0 pm mem 
branes, as described previously for Neospora caninum 
[HoWe, 1997 #1372]. 
Immunoscreen of S. neurona cDNA Library 
Construction and analyses of the cSn.1 S. neurona mero 
Zoite cDNA library has been described previously [HoWe, 
2001 #1787]. The library Was plaqued for 3 hrs at 420 C. on 
XLl-Blue MRF’ E. coli host cells (Stratagene) groWn on 
150 mm NZY agar plates. When plaques became visible, 
plates Were overlayed With nitrocellulose ?lters previously 
soaked in 10 mM isopropyl-[3-D-thiogalactopyranoside 
(IPTG) for an additional 3 hr incubation at 370 C. Filters 
Were lifted from the plates, Washed With TNT buffer (10 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% TWeen 20), and 
blocked in phosphate buffered saline (PBS), 5% dry milk, 
5% normal goat serum, 0.05% TWeen 20. 
Antigenic cDNA clones Were identi?ed by screening With 
cerebrospinal ?uid (CSF) from a horse that had been natu 
rally infected With S. neurona and exhibited a high titer of 
intrathecal antibodies against S. neurona in Western blot 
analysis. Prior to screening the S. neurona cDNA library, the 
CSF Was diluted 1:20 in PBS, 0.1% dry milk, 0.1% normal 
goat serum, 0.05% TWeen 20 and incubated for 30 min With 
?lters carrying plaque lifts of a previously-described N. 
caninum cDNA library [HoWe, 1999 #1759] to remove 
antibodies that Were reactive With E. coli and phage proteins. 
After adsorption of potential cross-reactive antibodies, the 
diluted CSF solution Was incubated for 1 hr With the cSn.1 
?lters. After Washing, ?lters Were incubated for 1 hr With 
goat anti-equine IgG conjugated to horseradish peroxidase 
(HRP) (Jackson Immunoresearch Labs, Inc.) diluted to 
1:10,000. Immuno-reactive phage plaques Were picked With 
sterile pipet tips and suspended in 40 ul of SM buffer (50 
mM Tris-HCl, pH 7.5, 100 mM NaCl, 8 mM MgSO4, 0.01% 
gelatin). The cDNA inserts Were PCR ampli?ed using the T3 
and T7 oligonucleotide primers, and the resulting products 
Were analyZed by agarose gel electrophoresis. Sequencing 
reactions using T3 primer Were conducted on the ampli?ed 
cDNAs to provide a preliminary identi?cation of the immu 
noreactive clones. Phagemid excision Was performed on 
selected cDNA clones, and plasmids Were rescued in SOLR 
cells according to the manufacturer’s protocol (Stratagene). 
S. neurona EST Database Searches and Sequence Analyses 
S. neurona homologues to previously-characterized coc 
cidian surface antigens Were identi?ed in the S. neurona 
clustered EST database (See, e.g., paradb.cis.upenn.edu/ 
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sarco/index.html) using the BLAST (basic local alignment 
search tool) set of programs [Altschul, 1990 #616]. At the 
time the database Was searched, it contained 686 consensus 
sequences that had been generated from 1883 S. neurona 
ESTs. Selected cDNAs Were obtained from the archived 
collection of EST clones and sequenced using ABI Prism 
BigDye Terminator Cycle Sequencing reaction mix (Perkin 
Elmer Applied Biosystems). The reactions Were puri?ed 
using Centri-Sep spin columns (Princeton Separations), and 
the eluted extension products Were resolved and analyZed on 
an ABI 310 Genetic AnalyZer. Sequence analyses Were 
conducted With Genetics Computer Group (GCG) softWare 
[Devereux, 1984 #1176] and programs available on the 
National Center for Biotechnology Information (NCBI) Web 
site (See, e.g., WWW.ncbi.nlm.nih.gov/) and the Expert Pro 
tein Analysis System (ExPASy) server of the SWiss Institute 
of Bioinformatics (See, e.g., WWW.expasy.ch/). Multiple 
sequence alignments Were performed using Multalin soft 
Ware [Corpet, 1988 #2046]. The sequence reported herein 
has been deposited into GenBank under accession number 
AY032845. 
Recombinant SnSAGl Expression and Generation of Poly 
clonal Antiserum 
The SnSAGl open reading frame Without the predicted 
amino-terminal signal peptide and the carboxyl-terminal 
hydrophobic tail Was ampli?ed by PCR from the pSnAg8 
cDNA using primers that introduce a NdeI restriction site 
prior to base 45 (numbered from the initiation codon) and an 
XhoI site after base 743. The ampli?cation product Was 
digested With NdeI and XhoI, ligated into NdeI/XhoI-di 
gested pET22b expression vector (Novagen), and trans 
formed into INVotF’ E. coli. The resulting expression plas 
mid, designated prSnSAG1, Was transformed into BL21 
CodonPlus E. coli (Stratagene), and a clone that expressed 
high levels of recombinant SnSAGl (rSnSAGl) Was 
selected for use. The histidine-tagged rSnSAG1 Was puri?ed 
by nickel-column chromatography according to the manu 
facturer’s protocol (Novagen), and monospeci?c polyclonal 
antisera Were produced against the puri?ed protein by 
immunization of a rabbit and rat (Cocalico Biologicals, 
Inc.). 
Western Blot Analysis 
Parasites Were lysed in sodium dodecyl sulfate (SDS) 
sample buffer supplemented With protease inhibitor cocktail 
(Sigma) and 2% 2-mercaptoethanol, and the lysates Were 
separated in 10% or 12% polyacrylamide gels [Laemmli, 
1970 #393]. Proteins Were transferred to nitrocellulose 
membranes by semidry electrophoretic transfer. in Tris 
glycine buffer (pH 8.3). Membranes Were blocked With PBS 
containing 5% nonfat dry milk, 5% goat serum, and 0.05% 
TWeen 20, and then incubated for 1 hr With primary anti 
body. After Washing, membranes Were incubated With HRP 
conjugated immunoglobulin G secondary antibody (Jackson 
Immunoresearch Labs, Inc.). Blots Were Washed, processed 
for chemiluminescence using Supersignal substrate (Pierce 
Chemical Company), and exposed to ?lm. 
Biotinylation of Surface Proteins and Precipitation With 
ImmobiliZed Streptavidin 
Approximately 3><107 freshly harvested meroZoites Were 
resuspended in 1 ml cold PBS (pH 7.8). Sulfo-N-hydroxy 
succinimide-biotin (Pierce) Was added to a concentration of 
0.5 mg/ml and incubated at room temperature for 30 min. 
The labeled parasites Were Washed tWice With 5 ml of PBS 
and stored at —200 C. 
The labeled parasite pellet Was lysed With 1 ml radio 
immunoprecipitation assay (RIPA) buffer (50 mM Tris [pH 
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7.5], 1% Triton X-100, 0.5% sodium deoxycholate, 0.2% 
SDS, 100 mM NaCl, 5 mM EDTA) supplemented With 
RNase, DNase, protease inhibitor cocktail, and the sample 
Was centrifuged at 16,000><g to remove the insoluble frac 
tion. The soluble proteins Were incubated With UltraLink 
immobilized streptavidin (Pierce), and the precipitated 
biotin-labeled protein fraction Was analyzed by Western 
blotting, as described above. 
lmmuno?uorescent Labeling of Extracellular and Intracel 
lular Parasites 
For detection of SnSAGl on extracellular parasites and in 
trails deposited by gliding parasites, freshly lysed merozoi 
tes Were suspended in fresh RPMI 1640 and incubated on 
poly-L-lysine-coated slides for approximately 30 min. 
Slides Were Washed With PBS, and the parasites Were ?xed 
in 2.5% formalin-PBS containing 0.01% glutaraldehyde. For 
detection of SnSAGl on intracellular parasites, merozoites 
Were inoculated onto BT cells groWn on LabTek chamber 
slides (Nunc). At 24 hr, 48 hr, or 72 hr post-inoculation, the 
cells Were ?xed in 2.5% formalin-PBS/0.01% glutaralde 
hyde and per'meablized With 0.2% TritonX-100. After incu 
bation With primary antibody, the slides Were rinsed, then 
incubated With ?uorescein isothiocyanate (FITC)-conju 
gated goat anti-rabbit IgG (Jackson Immunoresearch Labs, 
Inc.). The slides Were mounted in Vectashield With DAPI 
(Vector Laboratories, Inc.) and examined With a Zeiss axio 
scope equipped for epi?uorescence microscopy. 
Results 
Isolation and Analysis of Immunoreactive cDNA Clones 
A primary screen of the cSn.1 cDNA library identi?ed 
multiple immunoreactive phage plaques, and a total of 25 
plaques Were isolated and resuspended in SM bulfer. Ampli 
?cation of the cDNA inserts With T3 and T7 oligonucle 
otides revealed that 22 of the phage clones had similar 
lengths of approximately 1500 base pairs (bp), and sequence 
analysis using T3 primer indicated that these 22 cDNAs 
represent the same gene. A secondary screen Was performed 
on ?ve of the selected cDNAs, and tWo highly reactive 
phage clones, designated SnAgI.8 and SnAgI.9, Were chosen 
for further analyses. 
To obtain a preliminary identi?cation of the parasite 
protein encoded by the selected cDNAs, the SnAgI.9 clone 
Was used to a?inity purify antibodies that bind the antigen 
expressed by this clone, and the eluted antibodies Were used 
to probe a Western blot of S. neurona merozoite lysate. As 
shoWn in FIG. 1, the puri?ed antibodies reacted With an 
approximately 31-kDa antigen in reduced S. neurona lysate. 
Furthermore, the antigen revealed by the phage-puri?ed 
antibodies comigrated With a protein that is recognized by 
equine or rabbit antisera against S. neurona as the major 
immunodominant antigen of this parasite (FIG. 1, lanes 2 
and 3). This result implies that the 22 matching cDNA clones 
isolated during the library screen and represented by 
SnAgI.8 and SnAgI.9 encode the immunodominant antigen 
of S. neurona. 
Full-length sequence analysis of SnAgI.8 revealed a 
cDNA insert of 1493 nucleotides, With an open reading 
frame (ORF) that encodes a 276 amino acid protein. 
Sequence analysis of SnAgI.9 indicated that this clone Was 
virtually identical to SnAgI.8, although its 3' untranslated 
region (UTR) Was approximately 160 nucleotides longer due 
to an alternative polyadenylation site. A hydrophobicity plot 
of the encoded protein shoWed hydrophobic domains at both 
termini, Which correspond to a predicted signal peptide at 
the amino terminus and a GPI anchor addition sequence at 
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the carboxyl terminus (data not shoWn). The signal peptide 
cleavage is predicted to occur at Alals-Argl6 (SignalP; 
[Nielsen, 1997 #2047], and the most likely GPI transami 
dase cleavage site is predicted to be at Ala247-Asn248 (DGPI; 
SWiss Institute of Bioinformatics). A single N-glycosylation 
site Was predicted at residues 140-143. Removal of the 
N-terminal and C-terminal signal sequences results in a 
mature protein of 242 amino acids that has a predicted 
molecular Weight of 24.2 kDa before any potential post 
translational modi?cations (e.g., glycolipid anchor addition, 
glycosylation). 
To identify homology to previously characterized 
sequences, BLAST searches [Altschul, 1990 #616] of the 
non-redundant GenBank databases Were conducted With the 
SnAgI.8 coding sequence as the query. These searches 
revealed a statistically signi?cant similarity to the 31 kDa 
major surface antigen of Sarcocyslis muris [Eschenbacher, 
1992 #1767] and a less signi?cant but recognizable simi 
larity to several SAG2-related surface antigens from T 
gondii [Lekutis, 2000 #2049]. (FIG. 2). In conjunction With 
the Western blot analysis and the predictions of a signal 
peptide and a GPI-anchor addition, these results suggested 
that the gene represented by the SnAgI.8 and SnAgI.9 
cDNAs encodes an immunodominant surface antigen of S. 
neurona; consequently, We tentatively designated this pro 
tein SnSAGl, folloWing the genetic nomenclature that is 
utilized for the related apicomplexan parasites T gondii and 
N. caninum [Sibley, 1991 #13; HoWe, 1999 #1759]. 
The sequence analysis for SnSAG2, SnSAG3; and 
SnSAG4 as Well as for the SnGF Cluster sequences provided 
by the invention and set forth herein have been derived in a 
fashion similar to that set forth above for SnSAGl. These 
novel nucleotide sequences and protein sequences of Sar 
cocyslis neurona can be utilized in the production of vac 
cines and/or antigen/antibody kits for prevention and diag 
nosis of Sarcocyslis neurona infection. One preferred 
embodiment of the invention is a vaccine comprised of an 
alpha virus expression vector and nucleic acid selected from 
the nucleic acid sequences disclosed herein. 
Identi?cation. of S. neurona Surface Antigens and Expres 
sion as Recombinant Proteins 
Analysis of the S. neurona EST database revealed four 
paralogous proteins that are homologous to the SAG and 
SRS surface antigens of Toxoplasma gondii. Each S. neu 
rona gene Was predicted to encode a protein that possessed 
an amino-terminal signal peptide and a carboxyl-tenninal 
glycolipid anchor site, consistent With the proteins being 
surface antigens. Because of their similarity to Toxoplasma 
SAGs and their probable surface display on merozoites, the 
four S. neurona proteins Were designated SnSAGl, 
SnSAG2, SnSAG3, and SnSAG4. The four putative surface 
antigens Were each expressed as a recombinant protein in E. 
coli, and these Were used to immunize rabbits and rats for 
monospeci?c polyclonal antisera production. The resulting 
polyclonal antisera Were used in Western blot analysis of 
reduced (With 2-mercaptoethanol) S. neurona lysate to 
reveal each of the SnSAGs (See, FIG. 3). The mature forms 
of native SnSAGl and SnSAG4 are predicted to be approxi 
mately 24 kDa, but these antigens co-migrated at approxi 
mately 30-32 kDa and correspond to the immunodominant 
antigen Sn30 that has been described previously (See, FIG. 
3) (Granstrom et al., 1993; Liang et al., 1998). SnSAGl has 
also been identi?ed by others as a major surface antigen 
matching the immunodominant Sn30 band (Ellison et al., 
2002), but it is apparent that SnSAG4 likely contributes to 
the antibody reactivity at this molecular Weight. The mature 
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form of SnSAG2 is predicted to be about 12 kDa, but this 
antigen migrated at approximately 18-19 kDa and corre 
sponds to the previously described immunodominant Sn16 
antigen (See, FIG. 3) (Granstrom et al., 1993; Liang et al., 
1998). Mature SnSAG3 is predicted to be 23 kDa, but 
migrated at about 28 kDa (See, FIG. 3). The aberrant 
migration of the SnSAGs under reducing conditions is a 
characteristic that has been observed previously for the 
surface antigens of both T gondii (Burg et al., 1988; 
Cesbron-DelauW et al., 1994) and N. caninum (HoWe et al., 
1998). Importantly, the Western blot experiments demon 
strated that the recombinant forms of the SnSAGs are 
recogniZed by antibodies from S. neurona-infected horses. 
There is strong concordance betWeen antibody recognition 
of recombinant SnSAGl (rSnSAGl) and standard Western 
blot analysis of complete parasite antigen (i.e., S. neurona 
meroZoite lysate). Similar results Were obtained With rSn 
SAG2, rSnSAG3, and rSnSAG4. These data demonstrate 
the utility of using the rSnSAGs in ELISA formats to 
monitor antibody responses in S. neurona-infected horses. 
EnZyme-Linked Immunosorbent Assays (ELISAs) Based on 
Recombinant S. neurona Surface Antigens (rSnSAGs) 
The rSnSAGs expressed in E. coli have been shoWn in 
Western blots to be recogniZed by equine antibodies; con 
sequently, these recombinant antigens can be utiliZed as the 
key reagents for developing ELISAs based on single S. 
neurona antigens. An ELISA test Was developed for each of 
the four rSnSAGs that have been identi?ed by the invention. 
Expression and Puri?cation of Recombinant SnSAGs. 
To produce highly puri?ed recombinant forms of the 
SnSAGs, the genes for each antigen Were cloned into the 
pET22b expression plasmid from Novagen (Madison, Wis.). 
This plasmid vector provides a carboxyl-terminal fusion to 
a 6-residue oligohistidine domain (His-Tag), Which binds to 
metal ion af?nity columns and alloWs for the ef?cient 
one-step puri?cation of the expressed recombinant protein. 
Plasmid constructs Were transformed into BL21 (DE3) host 
cells (CodonPlus, Stratagene, Inc.), and expression of 
recombinant protein Was induced by addition of IPTG. 
Bacterial clones that reliably expressed the recombinant 
SnSAGs Were selected and cyropreserved for future study. 
The recombinant S. neurona surface antigens have been 
designated rSnSAGl, rSnSAG2, rSnSAG3, and rSnSAG4. 
To obtain recombinant protein, the appropriate bacterial 
clone Was groWn to logarithmic phase in LB medium, and 
protein expression Was induced by addition of IPTG to the 
culture. The recombinant protein Was extracted from inclu 
sion bodies With 6 M urea and puri?ed from the host cell 
lysate by Ni++-column chromatography according to the 
manufacturer’s protocol (His-Bind resin and buffers, 
Novagen). Urea Was removed by dialysis. If necessary, 
recombinant proteins Was concentrated by centrifugal ultra 
?ltration in Centricon-10 columns (Amicon). 
ELISA Assay 
The SN3 strain of S. neurona and the Oregon strain of 
Neospora hughesi Were maintained by serial passage in 
bovine turbinate cell monolayers. Upon lysis of the host cell 
monolayer, Zoites Were dispersed and ?ltered (3 .0 pm Nucle 
opore membrane ?lter, Whatman) to remove debris. Har 
vested parasites Were counted, Washed, and stored at —200 C. 
Concentration of puri?ed recombinant proteins prepared 
as described above Was determined by a calorimetric assay 
(Coomassie Plus Protein Assay Reagent, Pierce). Puri?ed 
rSnSAGl, rSnSAG2, rSnSAG3, and rSnSAG4 Were diluted 
in buffer (0.5 M NaCl and 20 mM Tris-HCl) Without urea to 
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?nal protein concentrations of 8.15 pg/ml, 23.0 pg/ml, 14.56 
pg/ml, and 10.3 pg/ml, respectively. 
Positive control serum samples Were obtained from tWo 
horses With histologically con?rmed EPM. The negative 
control sample for all assays Was a preinfection serum 
sample from a Weanling used in an experimental infection 
trial. Thirty six equine serum samples submitted for S. 
neurona serology testing Were used for standardiZation of 
the rSnSAG ELISAs. The samples had previously been 
classi?ed as positive or negative by Western blot. TWenty 
seven samples from horses of con?rmed EPM status Were 
obtained from a collection of the University of Kentucky 
Gluck Equine Research Center. All cases Were con?rmed by 
histological examination of central nervous system tissues 
for the presence of lesions consistent With EPM, as Well as 
Western blot analysis of CSF ?uids. Three equine serum 
samples from an S. fayeri challenge trial Were used to 
examine assay cross-reactivity. An N. hughesi positive con 
trol serum sample Was also evaluated. 
Native and recombinant proteins Were suspended in SDS 
PAGE buffer supplemented With protease inhibitor cocktail 
(Sigma) and separated on 12% polyacrylamide gels. For 
Western blot, proteins Were transferred to nitrocellulose 
membranes by semi-dry electrophoresis. Membranes Were 
blocked With PBS containing nonfat dry milk, 0.1% TWeen 
20, and 5% normal goat serum, and incubated for 1 hour in 
primary antibody solution. The membranes Were Washed, 
folloWed by incubation for 45 min. With horseradish per 
oxidase-conjugated secondary antibodies (Jackson Immu 
noResearch Laboratories, Inc.). Membranes Were processed 
for chemiluminescent detection using SuperSignal substrate 
(Pierce) and exposed to radiographic ?lm or documented 
With a FluorChem 8800 imaging system (Alpha Innotech 
Corp.). 
For rSnSAS ELISAs, high-binding 96-Well plates (Com 
ing) Were incubated overnight at 40 C. With 100 pl puri?ed 
rSnSAGl, rSnSAG2, rSnSAG3, or rSnSAG4 diluted to 0.20 
pg/ml, 1.00 pg/ml, 0.09 pg/ml, and 0.21 pg/ml, respectively. 
The plates Were rinsed With PBS/0.05% TWeen 20 and 
blocked for 1.5 h at room temperature With PBS/ 1% TWeen 
20/0.5% normal goat serum/0.001 g/ml nonfat dry milk. 
Primary sera or CSF Was diluted With PBS/1% TWeen 
20/0.5% normal goat serum/0.001 g/ml nonfat dry milk. One 
hundred pl aliquots of the sera or CSF containing mixed 
antibody populations Were added to duplicate Wells and 
incubated for 2 h at room temperature. The Wells Were 
rinsed, and then incubated for 2 h at room temperature With 
150 pl of horseradish peroxidase-conjugated goat anti-horse 
immunoglobulin G (IgG) secondary antibody (Jackson 
ImmunoResearch Laboratories, Inc.) diluted to 1:10,000 in 
PBS/1% TWeen 20/0.5% normal goat serum/0.001 g/ml 
nonfat dry milk. The Wells Were then again rinsed. The 
chromogenic substrate o-phenylenediamine dihydrochloride 
(Sigma) at 0.4 mg/ml (200 pl) Was added. After 10 min 
incubation, the reaction Was stopped With 50 pl of 3 M 
H2SO4, and OD490 Was measured in an Emu microplate 
reader (Molecular Devices). To account for interplate varia 
tion, the OD of each sample Was expressed as a percentage 
of the high positive standard on the plate. 
Serum antibody titers against rSnSAG4 Were detected in 
25 of 26 (96.2%) EPM-con?rmed horses (see FIG. 6). The 
rSnSAG2 and rSnSAG3 ELISAs yielded seropositive 
results in 24 of 26 (92.3%) EPM-con?rmed horses. Only 18 
of the 26 (69.2%) horses had detectable serum antibody 
titers against rSnSAGl. In total, 18 (81.8%), 18 (81.8%), 20 
(90.0%), and 21 (95.5%) of the 22 CSF samples had 
detectable antibody titers against rSnSAGl, rSnSAG2, rSn 























